Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

TENX Total Debt

Short-term and long-term borrowings combined.

Tenax Therapeutics, Inc.NASDAQ: TENX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt remains negative

Q1 FY2026 total debt was $0, compared with $0 a year earlier.

Context

  • Total debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Total Debt vs competitors

How TENX compares with its peers on the latest reported figures

  • TENX's Mar 2026 total debt of $0 is the 6th highest of the 7 companies compared; the peer median is $8.06M.
  • Total debt amounts to 0.0% of total assets for TENX, versus a peer median of 2.9%.
TENX Competitors Peer median
Total Debt for TENX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NERVMinerva Neurosciences, Inc.Jun 2026$71.74M ——0.1%
BOLDBoundless Bio, Inc.Mar 2026$48.29M -0.6%+111.5%34.3%
QTTBQ32 Bio Inc.Mar 2026$10.99M -41.5%-30.0%17.3%
SABSSAB Biotherapeutics, Inc.Jun 2026$5.13M -20.0%+0.1%2.2%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$1.44M -96.6%+2.2%3.7%
TENXTenax Therapeutics, Inc.Mar 2026$0 ——0.0%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding TENX) $8.06M-30.8%+1.2%2.9%

Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents5.58M2.12M9.79M94.85M97.57M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets(0)345.86K251.58K64K1.02M
Total Current Assets5.69M3.21M11.68M96.69M104.23M
Property, Plant & Equipment (Net)294.8K186.69K000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets8.44K9.55K1.12K00
Total Non-current Assets303.24K196.24K1.12K00
Total Assets5.99M3.4M11.68M96.69M104.23M
Account Payables859.64K448.43K2.07M3.16M6.04M
Short-term Debt0624.3K500.9K00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0245.39K236.88K1.34M898K
Total Current Liabilities1.56M1.85M3.59M4.69M7.16M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities183.59K64.2K000
Total Liabilities1.75M1.91M3.59M4.69M7.16M
Common Stock2.52K4.58K3001K
Retained Earnings(278.49M)(289.54M)(297.25M)(314.86M)(367.45M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity4.24M1.49M8.1M91.99M97.07M
Total Debt290.78K807.89K500.9K00
Net Debt(5.29M)(1.32M)(9.29M)(94.85M)(97.57M)

Tenax Therapeutics, Inc.

NASDAQ:TENX

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.